Detalhe da pesquisa
1.
Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
J Antimicrob Chemother;
79(4): 801-809, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38334390
2.
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
Antimicrob Agents Chemother;
65(6)2021 05 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33820773
3.
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Clin Infect Dis;
71(3): 667-671, 2020 07 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31738396
4.
Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother;
63(3)2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30617090
5.
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
JAC Antimicrob Resist;
5(2): dlad022, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36968951
6.
Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae.
JAC Antimicrob Resist;
5(5): dlad113, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37901589
7.
In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of ß-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution.
Antimicrob Steward Healthc Epidemiol;
3(1): e238, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38156228